Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.30 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1099223 | 0.85 | PAX8 (0.41) | MAPTSMN1; SMN2CYP2C19AURKARPS6KB1 | |
| SCHEMBL1097623 | 0.82 | MLYCD (0.39) | MAPTSMN1; SMN2CYP2C19AURKARPS6KB1 | |
| SCHEMBL1099324 | 0.82 | USP30 (0.40) | MAPTSMN1; SMN2CYP2C19AURKARPS6KB1 | |
| SCHEMBL1097539 | 0.80 | F2 (0.36) | MAPTSMN1; SMN2CYP2C19AURKARPS6KB1 | |
| SCHEMBL1098848 | 0.80 | MAPT (0.36) | MAPTSMN1; SMN2CYP2C19RAB9APOLB | |
| SCHEMBL15528455 | 0.79 | MAPT (0.39) | MAPTSMN1; SMN2RAB9APOLBALDH1A1 | |
| SCHEMBL1794562 | 0.78 | F2 (0.39) | MAPTSMN1; SMN2CYP2C19AURKARPS6KB1 | |
| SCHEMBL2529611 | 0.76 | MT-CO2 (0.42) | MAPTRAB9ANPC1PAX8 | |
| SCHEMBL12185886 | 0.76 | PAX8 (0.39) | MAPTSMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL30182335 | 0.75 | GRM2 (0.38) | MAPTSMN1; SMN2CYP2C19NR1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304507-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-10-20 | — | — | US | disclosed |
| US-20160304507-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-10-20 | — | — | US | disclosed |
| US-9409898-B2 | Substituted pyrazole compounds as CRAC modulators | LUPIN LIMITED (IN) | 2016-08-09 | — | — | US | disclosed |
| US-9409898-B2 | Substituted pyrazole compounds as CRAC modulators | LUPIN LIMITED (IN) | 2016-08-09 | — | — | US | disclosed |
| US-20150111925-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2015-04-23 | — | — | US | disclosed |
| US-20150111925-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2015-04-23 | — | — | US | disclosed |
| EP-2844656-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | Lupin Limited (IN) | 2015-03-11 | — | — | EP | disclosed |
| WO-2013164773-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2013-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111925-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | ORAI1, RYR2, RYR1 | MAPT 2296/4885SMN1; SMN2 2678/4885CYP2C19 779/4885 |
| US-20160304507-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | ORAI1, RYR2, RYR1 | MAPT 2296/4885SMN1; SMN2 2678/4885CYP2C19 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.